Novo Nordisk A/SNVONYSE
Loading
Earnings before interest, taxes, depreciation, and amortization
3Y CAGR
+23.3%/yr
vs +10.4%/yr prior
5Y CAGR
+19.4%/yr
Recent acceleration
Acceleration
+12.9pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.4x
Strong expansion
Streak
7 yr
Consecutive growthStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $143.94B | +4.8% |
| 2024 | $137.38B | +19.8% |
| 2023 | $114.63B | +49.3% |
| 2022 | $76.80B | +17.4% |
| 2021 | $65.39B | +10.3% |
| 2020 | $59.27B | +8.9% |
| 2019 | $54.43B | +5.4% |
| 2018 | $51.63B | -0.6% |
| 2017 | $51.95B | +1.8% |
| 2016 | $51.06B | - |